Acrux Limited · ASX:ACR
Acrux — H1 FY2017 Earnings Presentation
14 slides from Acrux's earnings presentation, Feb 17, 2017
Slide 1: 1H FY17 Results
For personal use only Acrux (ASX: ACR) 1H FY17 Results February 2017 Acrux 1H FY17
Slide 2: Forward looking statements
For personal use only Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Acrux to be mate
Slide 3: 1H FY17 outcomes
1H FY17 outcomes For personal use only Revenue 1H FY17: $14.3 million 1H FY16: $18.0 million Net Profit After 1H FY17: $6.3 million Tax 1H FY16: $9.7 million Cash 1H FY17: $31.7 million 1H FY16: $21.5 million Pipeline progress • Solid progress on first five generic projects • Contract manufacturing
Slide 4: Half year profit & loss
Half year profit & loss For personal use only 31 December 31 December Royalty revenue largely comprises Axiron revenue via % 2016 2015 our licensee Eli Lilly with minor contributions from sales of Estradiol in America and Europe. $'000 $'000 Axiron revenue at $13.7mil declined 10.5% from prior Royal
Slide 5: Half year cash flow
Half year cash flow For personal use only 31 December 31 December % 2016 2015 $'000 $'000 Cash received from conduct of business activities $10.4mil, down 28.9% or $A4.2mil on prior half- Cash flow from operating activities year due to: Receipts from product agreements 10,420 14,657 (28.9%) - Lenzet
Slide 6: Axiron IP Appeal
Axiron® IP Appeal For personal use only • United States District Court for the Southern District of Indiana judgment • Formulation and axilla application patents granted by the US Patent Office for Axiron® were invalidated • Patents therefore would not be infringed by the commercialisation of generi
Slide 7: Axiron sales
Axiron® sales For personal use only Axiron quarterly net sales 60 50 40 USD $M 30 20 10 - • AXIRON is used to treat adult males who have low or no testosterone due to certain medical conditions • Approved in the United States and selected other countries • Testosterone replacement therapy market is
Slide 8: Lenzetto (estradiol) spray
Lenzetto® (estradiol) spray Launched in Europe For personal use only • Lenzetto® is a hormone replacement therapy for women • Lenzetto® has been launched in a number of territories throughout 2016, through our licensee Gedeon Richter: Belgium Hungary Bulgaria Latvia Croatia Lithuania Czech Republic
Slide 9: Growth Strategy
Growth Strategy For personal use only Acrux is building a sustainable business model with a broader portfolio which leverages its existing topical expertise in compelling market segments How: Core competency – utilise current Measures of success: technology, skills and capabilities Portfolio wit
Slide 10: Total US pharma market size
Total US pharma market size For personal use only Aerosol Powders Other Topical • Oral market exceeds $200 billion Liquids • Injectable market exceeds $130 billion • Both oral and injectable markets are heavily competitive. • Topical transdermal market Oral exceeds $18 billion Injectable Source: Acr
Slide 11: Topical Generic Portfolio
Topical Generic Portfolio For personal use only • First three generic formulations US Transdermal and Topical market size completed. CMO selected and US$8.5 billion contracted. Generic market • 5 generic projects in active development sector 5 active generic • Topically applied generic products in U
Slide 12: Acrux antifungal development
Acrux antifungal development Onychomycosis For personal use only Indication For treatment of fungal infection (onychomycosis) of toenails and fingernails Formulation and intellectual property • Solution for topical administration • Improved formulation of efinaconazole selected • New patent has been
Slide 13: Future milestones
Future milestones • Draft and submit patent application for ACR065 • Patent filing submitted For personal use only for onychomycosis • Gedeon Richter to continue country specific • Ongoing launches of Lenzetto in the European Union • Scale up activities to manufacture exhibit • Scale up activities u
Slide 14: For personal use only
For personal use only Acrux 1H FY17